Drug Discovery

Many ATCC cell lines are already well defined models for drug discovery, and can provide researchers with a starting point for the development of pharmaceuticals and biologicals.

Physiologically relevant cell-based assays are critical for pre-clinical drug development. ATCC provides a vast collection of cell lines and other in vitro models needed to investigate the efficacy and safety of new chemical entities for such applications as high content screening, 3D culture, cytotoxicity, permeability assays, and receptor-ligand interactions. Additionally, many of these cell lines have been extensively characterized for drug sensitivity, mutational information, mRNA expression profiles, and patient background to facilitate rational drug design.

  • Cancer Resources
  • iPSCs
  • Tumor Cell Panels
  • Isogenic Cells
  • The Michael J. Fox Foundation Cell Lines
    • Use the links below to find the resources you need. Or, contact our ATCC Sales Representative at salesrep@atcc.org in the U.S. If you are an international customer, visit ATCC Distributors to find out if ATCC has an authorized distributor in your location.

      Angio-Ready Assay Ready System

      Angio-Ready is an assay-ready, single-use kit designed for the high-throughput monitoring of angiogenesis. This kit contains the ideal ratio of GFP-expressing hTERT-immortalized endothelial cells pre-mixed with hTERT-immortalized mesenchymal stem cells, and is supplied with complete growth medium. 

      Are you Angio-Ready? Choose from two available sizes:

      Two assays
      Ten assays


      ATCC offers a complete system of tri-lineage-capable, neural progenitor cells (NPCs); lineage marker-labeled NPCs; and expansion and differentiation media. Work with differentiating or terminally differentiated neurons, astrocytes, and oligodendrocytes much sooner - yield experimental results faster.

      Neural progenitor cells
      Neural progenitor expansion kit
      Dopaminergic differentiation kit

      Isogenic Cell Lines

      ATCC has recently employed CRISPR/Cas9 technology to create isogenic cell lines. The EML4-ALK Fusion-A549 Isogenic Cell Line is the first cell line derived from the parental non-small cell lung cancer cell line A549. Its sensitivity to ALK inhibitors compared to A549 cells makes it an ideal tool to study the tyrosine kinase signaling pathway and to screen for novel ALK inhibitors in anti-cancer drug discovery and development.

      EML4-ALK Fusion-A549